Introducing ACI’s Biosimilars & Innovator Biologics Advisory Board

American Conference Institute’s Biosimilars & Innovator Biologics Advisory Board was created as a part of ACI’s ongoing effort to provide industry leading content and a world-renowned speaker faculty. The board is composed of a selection of all-in-house advisers, including senior IP/Patent counsel from the leading pharmaceutical companies in the country and in some cases the world. This ‘inner circle’ counsels ACI on the impact of litigation trends and emerging topics.

Ali Ahmed

Senior Vice President, Biosimilars
Fresenius Kabi USA

Rebecca Charnas Grant

Senior Director | Associate General Counsel

Larry Coury

Vice-President, Associate General Counsel
Regeneron Pharmaceuticals

Henry Gu

SVP, Head of IP
Zentalis Pharmaceuticals

Brian McCormick

Vice President - Chief Regulatory Counsel, Head of Global Regulatory Policy
Teva Pharmaceuticals

Mira A. Mulvaney

Associate VP – Assistant General Patent Counsel, IP Litigation
Eli Lilly and Company

Sonia Tadjalli Oskouei

Vice President, Biosimilars and Specialty
Sandoz, Inc.

Dracey Poore

Director of Biosimilars Product and Solutions Marketing
Cardinal Health

Chuck Sholtz

Vice President, Intellectual Property
Legal Department
Nutcracker Therapeutics, Inc.

Paul Walden, Ph.D

Vice-President, Medical Affairs
Celltrion Healthcare Co., Ltd.

Gillian Woollett

VP, Head Regulatory Strategy and Policy
Samsung Bioepis